Stoke Therapeutics, Inc. (STOK)
29.70
+0.98
(+3.41%)
USD |
NASDAQ |
Jan 21, 15:35
Stoke Therapeutics Cash from Investing (Quarterly): 9.094M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -35.10M |
| Insmed, Inc. | -762.23M |
| Aldeyra Therapeutics, Inc. | 25.00M |
| Mirum Pharmaceuticals, Inc. | -2.227M |
| Moderna, Inc. | 700.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -30.37M |
| Cash from Financing (Quarterly) | 3.12M |
| Free Cash Flow | 52.37M |
| Free Cash Flow Per Share (Quarterly) | -0.5203 |
| Free Cash Flow to Equity (Quarterly) | -31.73M |
| Free Cash Flow to Firm (Quarterly) | -30.50M |
| Free Cash Flow Yield | 3.02% |